Proteomics

Dataset Information

0

Phosphoproteomics of primary human FLT3-ITD+ AML cells treated with gilteritinib

ABSTRACT: Primary human AML cells (newly diagnosed, prior to treatment initation) were obtained from donor after consent and AML blasts were isolated by standard Ficoll centrifugation. AML blasts were treated with FLT3 inhibitor gilteritinib (or DMSO vehicle control) at 10 nM concentration for 6 h, followed by harvest for LC/MS.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Cell, Leukocyte, Blood

DISEASE(S): Acute Leukemia

SUBMITTER: Sebastian Koschade  

LAB HEAD: Christian Münch

PROVIDER: PXD034080 | Pride | 2022-08-25

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
20220223_GT_SK_Revision_Phospho_F.msf Msf
20220223_GT_SK_Revision_Phospho_F1.raw Raw
20220223_GT_SK_Revision_Phospho_F2.raw Raw
20220223_GT_SK_Revision_Phospho_F3.raw Raw
20220223_GT_SK_Revision_Phospho_F4.raw Raw
Items per page:
1 - 5 of 8
altmetric image

Publications

Internal tandem duplications (ITD) in the receptor tyrosine kinase FLT3 occur in 25 % of acute myeloid leukemia (AML) patients, drive leukemia progression and confer a poor prognosis. Primary resistance to FLT3 kinase inhibitors (FLT3i) quizartinib, crenolanib and gilteritinib is a frequent clinical challenge and occurs in the absence of identifiable genetic causes. This suggests that adaptive cellular mechanisms mediate primary resistance to on-target FLT3i therapy. Here, we systematically inve  ...[more]

Similar Datasets

Proteomics Translatome proteomics of primary human FLT3-ITD+ AML cells treated with FLT3 inhibitors quizartinib, crenolanib, gilteritinib
2022-08-25 | PXD034081 | Pride
Proteomics Translatome proteomics of human AML cells treated with FLT3 inhibitors quizartinib, crenolanib, gilteritinib
2022-08-25 | PXD023125 | Pride
Proteomics Phosphoproteomics of human MV4-11 AML cells treated with Gilteritinib
2022-08-25 | PXD023123 | Pride
Proteomics DNR pulse treatment of primary AML
2022-10-15 | PXD030280 | Pride
Proteomics PAM complex sequesters from TIM translocon and becomes part of an insoluble protein fraction under protein folding stress
2022-09-03 | PXD022524 | Pride
Proteomics PAM complex sequesters from TIM translocon and becomes part of an insoluble protein fraction under protein folding stress
2022-09-03 | PXD022530 | Pride
Proteomics,Multiomics Functional translatome proteomics reveal converging regulation by mTORC1 and eIF2α
2019-12-06 | PXD014377 | Pride
Proteomics,Multiomics Functional Translatome Proteomics Reveal Converging and Dose-Dependent Regulation by mTORC1 and eIF2α
2019-12-09 | PXD015438 | Pride
Proteomics Protein import defects induce mitophagy without membrane depolarization
2022-09-03 | PXD022560 | Pride
Proteomics Endogenous anti-tumorigenic nitro-fatty acids potently suppress the ubiquitin-proteasome system
2024-03-26 | PXD023372 | Pride